BIG NEWS: Roche/Genentech Announce Site Locations for GENERATION HD1 Trial of RG6042

Roche-Genentech announce sites1.JPG

Roche/Genentech announce the locations, including 20 sites in the U.S. and 6 in Canada, for their phase 3 study - called GENERATION HD1 - to test efficacy of the huntingtin-lowering therapy RG6042.

This study is open and currently recruiting! This will be a 2-year study in people with early diagnosed HD, involving monthly spinal injections to deliver RG6042 or a placebo, as well as clinical tests and scans to understand the effect of the drug on HD symptoms. Around 660 people age 25-65 will be recruited at approximately 90 sites across the world.

Read the full press release.